European journal of gastroenterology & hepatology · 2026
Efficacy and safety of tenapanor in the management of irritable bowel syndrome with constipation: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aref Ahmed, Aldemerdash Mohamed A, Mohamed Islam, Abdallfatah Abdallfatah, Abosheaishaa Hazem, Telbany Ahmed, Dahiya Dushyant Singh, Ghoz Hassan, Duong Nikki
Аннотация
INTRODUCTION: Irritable bowel syndrome with constipation (IBS-C) is a common gastrointestinal disorder that significantly impacts quality of life. Tenapanor, a sodium/hydrogen exchanger inhibitor, shows promise in managing IBS-C. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tenapanor 50 mg compared with placebo.
METHODS: This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was conducted on 7 October 2024 across PubMed , Cochrane , Embase , Scopus , and Web of Science databases. We included randomized controlled trials (RCTs) focusing on adult IBS-C patients aged 18-75. Quality assessment was performed using the risk of bias 2 tool. Primary outcomes included responder rates for abdominal symptoms (pain, discomfort, bloating, cramping, fullness) and complete spontaneous bowel movements (CSBM). Secondary outcomes comprised treatment-related adverse events (AEs) and those leading to treatment discontinuation. Data analysis was conducted using R software.
RESULTS: Three RCTs involving 1378 patients were included. Tenapanor significantly improved symptoms versus placebo, including bloating [relative risk (RR) = 1.32; 95% confidence interval (CI), 1.15-1.51], cramping (RR = 1.27; CI, 1.13-1.44), discomfort (RR = 1.37; CI, 1.21-1.56), fullness (RR = 1.37; CI, 1.20-1.58), pain (RR = 1.37; CI, 1.17-1.49), and CSBM (RR = 1.54; CI, 1.24-1.91). However, tenapanor was associated with higher rates of treatment-related AEs (RR = 2.3; CI, 1.72-3.06) and AEs leading to discontinuation (RR = 9.08; CI, 3.63-22.71).
CONCLUSION: Tenapanor is effective in improving IBS-C symptoms but has a higher incidence of treatment-related AEs. Further studies are needed to evaluate its long-term safety.
METHODS: This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was conducted on 7 October 2024 across PubMed , Cochrane , Embase , Scopus , and Web of Science databases. We included randomized controlled trials (RCTs) focusing on adult IBS-C patients aged 18-75. Quality assessment was performed using the risk of bias 2 tool. Primary outcomes included responder rates for abdominal symptoms (pain, discomfort, bloating, cramping, fullness) and complete spontaneous bowel movements (CSBM). Secondary outcomes comprised treatment-related adverse events (AEs) and those leading to treatment discontinuation. Data analysis was conducted using R software.
RESULTS: Three RCTs involving 1378 patients were included. Tenapanor significantly improved symptoms versus placebo, including bloating [relative risk (RR) = 1.32; 95% confidence interval (CI), 1.15-1.51], cramping (RR = 1.27; CI, 1.13-1.44), discomfort (RR = 1.37; CI, 1.21-1.56), fullness (RR = 1.37; CI, 1.20-1.58), pain (RR = 1.37; CI, 1.17-1.49), and CSBM (RR = 1.54; CI, 1.24-1.91). However, tenapanor was associated with higher rates of treatment-related AEs (RR = 2.3; CI, 1.72-3.06) and AEs leading to discontinuation (RR = 9.08; CI, 3.63-22.71).
CONCLUSION: Tenapanor is effective in improving IBS-C symptoms but has a higher incidence of treatment-related AEs. Further studies are needed to evaluate its long-term safety.